Bhatt Padmanabh P. has reported a series of significant stock transactions following the recent merger of Supernus Pharmaceuticals, Inc. with Indivior Pharmaceuticals, Inc. This merger, effective November 2, 2026, has led to a restructuring of ownership for Supernus, which is now a wholly-owned subsidiary of Indivior.

The filing, dated November 4, 2026, indicates that Padmanabh, who serves as the Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus, has disposed of shares in Supernus Pharmaceuticals and acquired shares in the newly formed entity, Supernus, Inc. This transaction is part of the broader trend of consolidation in the pharmaceutical industry, reflecting ongoing strategic movements among key players.

Background

Supernus Pharmaceuticals, Inc., a company incorporated in Delaware, operates within the pharmaceutical preparations sector. The company focuses on developing and commercializing products for the treatment of central nervous system disorders. The recent merger with Indivior Pharmaceuticals marks a significant shift in its operational landscape.

What the Filing Says

According to the filing (accession number 0001539215-26-000014), Padmanabh reported the disposal of 18,637 shares of Supernus common stock, which were automatically converted into shares of Indivior upon the merger. Additionally, he acquired 3350 performance share units and other equity awards as part of the merger agreement.

Impact

This merger and the subsequent transactions may affect various stakeholders, including employees, investors, and competitors in the pharmaceutical sector. The consolidation could lead to enhanced product offerings and operational efficiencies for the newly formed Supernus, Inc. However, it may also create challenges for competitors as they adapt to the changing market landscape.

What's Next

The filing does not say what happens next.